Vaccines for pancreatic cancer

Kevin C. Soares, Lei Zheng, Barish Edil, Elizabeth M. Jaffee

Research output: Contribution to journalReview articlepeer-review

Abstract

Pancreatic ductal adenocarcinoma (PDA) remains a highly lethal disease; new therapeutic modalities are urgently needed. A number of immunotherapies tested in preclinical models have shown promise. Early-phase clinical trials have demonstrated evidence of immune activation that in some cases correlates with clinical response. Moreover, recent evidence delineates the intricate role of inflammation in PDA, even at its earliest stages. Pancreatic ductal adenocarcinoma is thus ripe for immunotherapy; however, significant challenges remain before success can be realized. Future studies will need to focus on the discovery of novel PDA antigens and the identification of the multiple immune suppressive pathways within the PDA tumor microenvironment that inhibit an effective PDA-targeted immune response. Technologies are now available to rapidly advance discovery. Rapid translation of new discoveries into scientifically driven clinical trials testing combinations of immune agents will likely continue to shift the procarcinogenic tumor environment toward the most potent anticancer response.

Original languageEnglish (US)
Pages (from-to)642-652
Number of pages11
JournalCancer Journal (United States)
Volume18
Issue number6
DOIs
StatePublished - Nov 2012

Keywords

  • Pancreatic cancer
  • cancer vaccine
  • immune therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Vaccines for pancreatic cancer'. Together they form a unique fingerprint.

Cite this